Back to Search
Start Over
Supplementary Figure 3 from TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- PDF file - 130K, Anti-tumor activity of TAK-960 in MV4-11luc disseminated leukemia model.
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....15cb82c738efd1b506e891eb7ac6552a
- Full Text :
- https://doi.org/10.1158/1535-7163.22498084